Sex-Specific Cord Blood DNA Methylation Signatures for Childhood ADHD Symptoms

Authors

Markos Tesfaye MD, PhD,[1,2,3,4] Solveig Løkhammer MD, PhD candidate,[1,5] Dinka Smajlagic PhD,[6,7] Anne-Kristin Stavrum PhD,[1,5] Kira D. Hoeffler PhD candidate,[1,5,8,9] Christian M. Page PhD,[10] Jonelle Villar PhD candidate,[1,5] Alexey Shadrin PhD,[4] Mona Bekkhus PhD,[7] Tetyana Zayats MD, PhD,[7,11,12,13] Stephanie Le Hellard PhD[1,5,9]

Affiliations

[1] Department of Clinical Science, University of Bergen, Bergen, Norway

[2] Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University, Brooklyn, NY, USA

[3] Institute for Genomics in Health, SUNY Downstate Health Sciences University, Brooklyn, NY, USA

[4] Center for Precision Psychiatry, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway

[5] Dr. Einar Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway

[6] Institute for Behavioral Genetics, University of Colorado Boulder, Boulder, USA

[7] PROMENTA Research Center, Institute for Psychology, University of Oslo, Oslo, Norway.

[8] Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA, USA

[9] Bergen Center for Brain Plasticity, Haukeland University Hospital, Bergen, Norway

[10] Department of Physical Health and Ageing, Division for Public Health and Prevention, Norwegian Institute of Public Health, Oslo, Norway

[11] Analytic and Translational Unit, Massachusetts General Hospital, Boston, MA, USA.

[12] Stanley Center for Psychiatric Disorders, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

[13] Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Corresponding authors

Markos Tesfaye, Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University, 450 Clarkson Avenue, Psychiatry – MS 1203, Brooklyn, NY 11203, USA
markos.woldeyohannes@downstate.edu

Stéphanie Le Hellard, Department of Clinical Sciences, University of Bergen, Postboks 7804 5020 Bergen, Norway,
stephanie.lehellard@uib.no

Abstract

The underdiagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) in females, particularly those with the inattentive presentation, highlights a critical gap in clinical care. While DNA methylation may be tissue-specific, accessible peripheral measures such as cord blood can provide valuable insights into early-life risk and serve as potential biomarkers for detection. We aimed to discover sex-specific epigenetic markers in cord blood associated with childhood ADHD symptoms, which could illuminate early-life risk mechanisms and inform improved detection strategies.

Method

We conducted sex-stratified epigenome-wide association study (EWAS) of cord blood DNA methylation in relation to ADHD symptoms among child participants (n=2,417; 47% females) of the Norwegian Mother, Father, and Child study (MoBa). We tested for sex-interaction effects and analyzed inattention and hyperactivity/impulsivity symptoms separately.

Results

We identified 21 differentially methylated CpG positions (DMPs). The majority (n=13) were associated with inattention symptoms exclusively in females, and all exhibited significant sex-interaction effects (corrected p-value <0.05). There was no overlap between the DMPs, or differentially methylated regions (DMRs) identified in females and males, and the epigenetic signatures for inattention and hyperactivity/impulsivity were largely distinct. Several annotated genes (e.g., *PNPO, KDM5B*, and *GABRP*) have recognized roles in neurotransmission and neurodevelopment.

Conclusion

Our findings demonstrate that the peripheral epigenetic profile at birth associated with later ADHD is remarkably different between sexes. This highlights the value of sex-stratified analyses and suggests that peripheral epigenetic markers hold promise for the development of tools for early detection.

Keywords: ADHD, inattention, hyperactivity, 'DNA methylation', 'sex differences', epigenetics

Introduction

Attention Deficit Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder affecting 5 to 8% of children and adolescents globally,[1,2] with symptoms persisting into adulthood in most affected individuals. While primarily characterized by pervasive inattentiveness and hyperactivity/impulsivity, it presents with a heterogeneous combination of symptoms, impacting clinical recognition and treatment.[3] The higher prevalence in males than in females in childhood and adolescence[1,2] tends to diminish in adulthood, partly due to significantly delayed recognition of females with predominant symptoms of inattention.[4,5] Although genetic and environmental factors contribute to ADHD risk,[6,7] the molecular mechanisms underlying these sex differences in presentation and epidemiology are not fully understood.[8]

Epigenetic markers such as DNA methylation level, which partly mediate genetic and environmental effects, offer a promising avenue to investigate early-life molecular signatures of ADHD.[9] Considerable sex differences in brain DNA methylation profiles are documented across different stages of development,[10] and these differences are also detectable in peripheral tissues, such as white blood cells at birth.[11] While epigenome-wide association studies (EWAS) have begun identifying cord blood DNA methylation marks associated with ADHD,[12,13] results across studies have been inconsistent.[14-17] This heterogeneity may arise from differences in sample size, phenotype assessment methods, and a critical, yet often overlooked factor - failure to adequately account for sex differences in the analytical approach. To our knowledge, no prior EWAS has conducted a comprehensive, sex-stratified investigation of ADHD symptoms to identify female-specific and male-specific DNA methylation signatures.

We recently demonstrated that meta-analyses accounting for sex can enhance epigenetic discovery when sex differences are present.[18] Applying this approach to ADHD is particularly relevant given the reported sex differences in its epidemiology and clinical presentation.[1,2] Therefore, we performed sex-stratified (male-only or female-only) and sex-differentiated (combining male-only and female-only through meta-analysis) analyses to identify DNA methylation signatures in cord blood associated with the total ADHD symptom score at the age of eight among children in the Norwegian Mother, Father and Child Study (MoBa). We also investigated DNA methylation marks associated with specific symptom domains of inattention and hyperactivity/impulsivity. Our goal was to identify early-life risk markers in cord blood that precede the onset of ADHD symptoms, providing insights into sex specific pathways to

ADHD and its subtypes, and contributing to the groundwork for future biomarker development that could improve early identification.

Materials and Methods

Cohort characteristics (MoBa)

The Norwegian Mother, Father and Child (MoBa) study is a nation-wide longitudinal cohort with participants recruited between 1999 and 2008. On average 41% of the pregnant women during that period consented to participate. Overall, the MoBa cohort includes approximately 114,500 children, 95,200 mothers and 75,200 fathers.[19] The current study was based on version 12 of the quality-assured data files released for research in 2022. The establishment of MoBa and the initial data collection were approved by the Norwegian Data Protection Agency and the Regional Committees for Medical and Health Research Ethics. Participating mothers provided written informed consent. The MoBa study is regulated by the Norwegian Health Registry Act. The current study was approved by the Regional Committees for Medical and Health Research Ethics (REK 2018/1898).

DNA methylation data

This study was nested within the larger MoBa cohort and included four sub-cohorts of children for whom DNA methylation was obtained in different batches. The sub-cohorts correspond to MoBa1 (met001), MoBa2 (met002), MoBa4 (met004), and MoBa8 (met008) sub-studies. Cord blood sample collection, phenotype, and covariate data collection were similar. (https://github.com/folkehelseinstituttet/mobagen/wiki/Methylation#documentation-valid-for-all-data-sets)

The MoBa1 sub-study initially comprised a random sample of children, including cases of asthma (n=1,010). DNA methylation typing was assessed in 2011 using Illumina Infinium HumanMethylation450 (450K) array (Illumina, San Diego, CA). Participants with complete data on ADHD symptoms and all covariates (n=655) were included in the current analysis. The MoBa2 sub-study consisted of a random sample (n=604) of children with and without asthma who had DNA methylation typed in 2013 using the 450K array.[11] Among these, a subset (n=330) who had complete data on ADHD symptoms and covariates were included. The MoBa4 sub-study included a random sample of 1,952 children with DNA methylation data. Of these, 896 children with complete data on ADHD symptoms and covariates were included in the current study. The MoBa8 sub-study comprised a random sample of children selected for a diabetes and obesity study (n=1,206). From this cohort, 491 children had complete data on ADHD symptoms and covariates, and were included. DNA methylation profiling for MoBa4

and MoBa8 was performed using the Illumina Infinium HumanMethylationEPIC V1 array in 2019 and 2021, respectively (Illumina, San Diego, CA).

Phenotype and covariate data

ADHD symptoms were assessed using the Parent/Teacher Rating Scale for Disruptive Behavior Disorders (RS-DBD) at the age of eight.[20] RS-DBD has 18 items based on the DSM-IV ADHD symptoms. Nine of the items were related to the inattention cluster of symptoms, while the remaining nine items inquired about hyperactivity and impulsivity. Each item is rated on a 4-point Likert scale ranging from 1 to 4, with higher scores indicating greater symptom burden. The total ADHD symptom score was calculated from the responses to all 18 items, ranging from 18 to 72. The '*inattention*' and 'h*yperactivity/impulsivity*' subscale scores were computed from the corresponding nine items and ranged from 9 to 36. The RS-DBD questionnaires were filled out by the mothers of children included in the MoBa study.

Covariates: - sex, birth weight in grams, and gestational age in weeks were recorded at birth and obtained from the Medical Birth Registry of Norway. We computed smoking scores from DNA methylation data.[21,22] Similarly, estimated blood cell-type proportions were obtained by applying the Houseman method as described previously.[12,23]

DNA methylation data

Details of the protocol for the collection and storage of cord blood samples in the MoBa study are described elsewhere.[24] In brief, umbilical cord blood samples were collected at birth and stored at -80 degrees Celsius at the study Biobank.[24] Bisulfite conversion was performed using the EZ-96 DNA Methylation kit (Zymo Research Corporation, Irvine, CA).[12]

Quality control and data processing were performed independently for each of the four sub-cohorts. The intensity (i.dat) files were processed using the *minfi* package to generate methylation level measure (beta values) for each CpG site (i.e., the fraction of methylated sites per sample calculated as the ratio of methylated and unmethylated fluorescent signals in the mixture of blood cells) and detection *p*-values. Background subtraction was performed using out-of-band probes (ss-Noob). The Beta Mixture Quantile (BMIQ) method was applied to normalize for the differences in the Illumina probe designs.[25] Control probes, non-autosomal probes, and CpGs with > 10% missing methylation data were removed. Samples with an average detection *p*-value across all probes < 0.05 and samples with a mismatch between the reported and methylation-derived sex were also removed.[12] Detailed quality control steps are provided at: https://github.com/folkehelseinstituttet/mobagen/wiki/MethylationQC.

Epigenome-wide association analysis (EWAS)

Three sets of EWASs were conducted, focusing on the total ADHD symptoms, the inattention domain, and the hyperactivity/impulsivity domain. All EWASs were performed as sex-stratified; therefore, they comprised data from only female or male children. For each EWAS, linear regression analysis was performed using the *limma* package to identify differentially methylated CpG positions (DMPs) associated with the respective ADHD symptoms.[26] The methylation beta values for each probe were regressed against the symptom scores (total ADHD symptom scores, inattention domain, or hyperactivity/impulsivity domain scores) in a model that included the following covariates: birth weight, gestational age at delivery, cord blood cell type proportions, smoking scores, two ancestry principal components (PCs) computed from methylation data,[27] five methylation PCs, and 30 control probe PCs. Quantile-quantile (QQ) plots of models with different numbers of PCs were compared, and the one with the least inflation and a lambda value closest to 1 was selected. Probes mapped on the sex chromosomes (X and Y) were excluded from the analyses.

Meta-analyses

Meta-analyses were performed for sex-stratified (male-only or female-only) and sex-differentiated (combination of all male-only and female-only summary statistics) models. The sex-stratified meta-analysis involved four datasets, and the sex-differentiated meta-analysis included eight datasets. In all meta-analyses, effect sizes and standard errors were analyzed using the *metagen* function of the *meta* R-package. The implementation employs a standard inverse variance meta-analysis, where the pooled effect sizes are calculated as the weighted average of the effect sizes in each EWAS. Probes with results from EWAS in at least two sub-cohorts were included in the meta-analyses. Based on the evidence presented on adequate control for false positive results,[28] DMPs with *p*-value less than 9.0×10^{-8} on the fixed effects model were considered significant.

We applied the *comb-p* procedure to identify differentially methylated regions (DMRs).[29,30] The specific parameters used were seed p-value = 0.001 and maximum distance between probes of 750 base pairs. DMRs with a minimum of four probes were identified with a Sidak-adjusted p-value threshold of $p < 0.05$.[30]

Functional regulation and gene set analyses

The identified DMPs and DMRs were annotated to genes using the '*annotatr*' package.[31] Annotations were obtained by selecting 'hg19_basicgenes', which provided genes for DMPs and DMRs in the promoter, 5'UTR, 3'UTR, exon, intron, and 1kb to 5kb upstream regions. Enrichment of genes for pathways of biological processes, molecular functions, and cellular components was tested using a gene set analysis platform (*geneontology.org*).

We examined the regulation by genetic variants of the methylation status at the identified DMPs. This was achieved by exploring the DMPs for a list of known *cis*-acting methylation quantitative trait loci (*me*QTLs) in the human blood at birth.[32] We also compared the effect directions of the known *me*QTLs with those observed in our analyses.

Sex-interaction effects, and overlap of DMPs and DMRs

Sex interaction effects were tested for all epigenome-wide significant DMPs, and their *p*-values were corrected for the respective numbers of tests. First, the sex interaction (sex*ADHD, sex*inattention, sex*hyperactivity/impulsivity) term was added to the EWAS model described for the main analysis. The effect sizes and standard errors of the sex interaction term from each sub-study data were meta-analyzed, and the effect sizes and *p*-values are presented.

We compared the overlap across epigenome-wide significant DMPs and DMRs in females, males, and individuals with inattention-only and hyperactivity/impulsivity-only symptoms. Additionally, we expanded the comparison for the top 1000 CpGs to examine the pattern of overlap for CpGs with suggestive *p*-values, and these overlaps are presented in a Venn diagram.

Results

Cohort characteristics

Complete data on ADHD symptoms, DNA methylation, and covariates were available for 2,417 (47.2% females) children. Table 1 provides the characteristics of the study participant children across the four sub-cohorts. The mean birth weights were higher for males (p-value < 0.05). On a non-parametric (Mann–Whitney) test, males had higher ADHD, inattention, and hyperactivity/impulsivity symptom scores than females (p-value < 0.05).

All ADHD symptoms and DNA methylation

In males, ADHD symptoms were associated with one DMP hypomethylation at cg16317998, and four DMRs, including at chr17:46018731-46019018 (*PNPO*). In females, eight DMPs showed significant association with ADHD symptoms, two exhibiting hypermethylation: cg01123478 and cg15676735 (*ZBTB3*), and the rest showing hypomethylation (Figure 1, Table 2). Also, 11 DMRs, including chr1:202778575-202778870 (*KDM5B*), were identified in females. *KDM5B* encodes for the enzyme, histone demethylase, involved in epigenetic regulation of genes. Four DMRs, but no DMPs, reached genome-wide significance in the sex-differentiated meta-analysis that included males and females (Table 2, Supplementary file: Tables S1–S3).

Inattention symptoms and DNA methylation

In males, three DMRs, chr1:84326462-84326670 (*MIR548AP*), chr2:54087008-54087210 (*GPR75*), and chr6:38682982-38683222 (*DNAH8*), but no DMPs showed epigenome-wide significant associations with inattention symptoms. Thirteen DMPs and twenty-one DMRs were associated with inattention symptoms in females. Hypomethylation was linked to inattention symptoms in all but two DMPs, cg00152322 and cg01123478. One DMC, cg03072921, and five DMRs, including chr11:6291339-6292616 (*CCKBR*), had an epigenome-wide significant association with inattention in the sex-differentiated analysis (Table 3, Supplementary file: Tables S4–S6).

Hyperactivity/impulsivity symptoms and DNA methylation

Hypomethylation at cg16317998 (in males), cg05928306 (in females), and cg13426208 (in sex-differentiated) meta-analyses was associated with hyperactivity/impulsivity symptoms (Table 3). Three and eight DMRs were associated with hyperactivity/impulsivity symptoms in males and females, respectively (Table 3, Supplementary file: Tables S7–S8). Three DMRs

were identified for both inattention and hyperactivity/impulsivity symptoms, namely chr6:38682982-38683222 (*DNAH8*) in males, and chr6:29648275-29648629 (*ZFP57*) and chr17:6796745-6797120 (*ALOX12P2*) in females (Supplementary file: Tables S5 – S8).

Functional regulation and gene set analyses

DMPs and DMRs located in the promoter, 5'UTR, 3'UTR, exon, intron, or within 1kb to 5kb upstream regions were annotated to the nearby genes (Tables 2 & 3, Supplementary file: Tables S1-S8). None of the pathways in the gene set analyses for genes annotated to DMPs and DMRs reached statistical significance after correction for multiple testing. Genes annotated to identified DMPs cg15676735 (*ZBTB3*), cg03072921 (*ZNF789*), cg13328808 (*TBX19*), and cg16994531 (*LPIN1*) are involved in transcriptional regulation, regulation of developmental processes, and lipid metabolism. Genes annotated to DMPs, cg07602513 (*EEF2K*), cg10481534 (*PARP6*), and cg16712581 (*HERC3*) are involved in the regulation of protein synthesis and posttranslational modifications.

In the *me*QTL database, the methylation level of cg00152322 at birth is influenced by over 150 known *cis*-acting variants with mixed effect directions. There are no known *cis-me*QTL in blood at birth for the other DMPs.

Sex-interaction effects, and overlap of DMPs and DMRs

Our analyses revealed that the association between cord blood DNA methylation and ADHD symptoms is predominantly sex specific. This is underscored by the finding that all 18 DMPs identified in females exhibited significant sex-interaction effects, confirming their association is specific or significantly stronger in females (Supplementary Tables S9-S11). We found virtually no overlap between the sexes: none of the top DMPs for inattention symptoms were shared, and the overlap for hyperactivity/impulsivity was minimal (Figure 2). This pattern of non-overlap was also observed in DMR analyses, which identified distinct sets of DMRs in females and males (Supplementary Tables: S2-S3 & S5-S8). Overall, the cord blood DNA methylation profiles associated with childhood total ADHD, inattention-only, and hyperactivity/impulsivity-only symptoms show minimal overlap between males and females.

Discussion

Our sex-stratified epigenome-wide association meta-analysis of cord blood revealed that the DNA methylation landscape associated with childhood ADHD symptoms is largely sex-specific. The identification of multiple female-specific DMPs and DMRs, which became attenuated when female and male data are combined, highlights the importance of sex-informed analytical approaches. Furthermore, the epigenetic signatures of inattention and hyperactivity/impulsivity showed notable differences, suggesting distinct biological correlates for these clinical subtypes.

Exposure to an adverse intra-uterine environment, such as maternal obesity, hypertension, and medications, contributes to the risk of ADHD.[33] Thus, DNA methylation marks we identified in cord blood may reflect the biological embedding of in utero exposure to one or more adversities.[34] The observation that most identified DMPs do not have known *me*QTLs[32] (genetic variants influencing their methylation) suggests they are markers of environmental exposures, although a role for genetic influences remains possible given the established effect of gene-environment interaction in shaping the epigenome.[35]

Several genes (*EFNA4*, *KDM5B*, *GABRP,* and *PNPO*) annotated to the identified DMPs and DMRs have established roles in neurodevelopment. For instance, *PNPO* is crucial for the synthesis of vitamin B6, a cofactor in the biosynthesis of monoamine neurotransmitters.[36,37] Also, vitamin B6 precursor (metadoxine) was shown to attenuate symptoms of ADHD.[38] Similarly, mutations in *KDM5B* have been implicated in developmental disorders, including ADHD and autism spectrum disorder.[39-41] *GABRP* encodes for a subunit of the GABA receptor, which is consistent with emerging evidence on GABAergic neurotransmission dysfunction in ADHD.[42,43] While the tissue specificity of DNA methylation must be considered, the convergence of these annotated genes on plausible neurobiological pathways for ADHD supports the potential of these cord blood signatures as markers of early-life risk.

The molecular mechanisms for the sex differences in prevalence and clinical presentation of ADHD are not well understood.[8] While a genome-wide association study has not found remarkable sex differences in genetic architecture,[44] our findings demonstrate notable sex differences at the epigenetic level. The lack of overlap between the DMPs and DMRs identified in males and females indicates that the peripheral epigenetic profiles associated with ADHD symptoms differ at birth. The identification of a larger number of DNA methylation signatures in females, despite comparable sample sizes, is intriguing. One plausible explanation is the

'female protective effect' model, which posits that females require a higher burden of risk factors to express the phenotype,[45,46] a pattern also observed in other neurodevelopmental conditions.[47] Most importantly, the female-specific cord blood DNA methylation signatures, especially for inattention, hold translational promise. They could form the basis for biomarkers to help identify at-risk females, thereby mitigating diagnostic disparities and enabling timely intervention.[3,4,48,49]

Our stratification by symptom domain also provides insight into the heterogeneity of ADHD. The contrasting DNA methylation signatures of inattention and hyperactivity/impulsivity enhance our understanding of their potentially distinct biological correlates and complement reported differences in genetic architecture.[50] Such stratification is crucial for biological discovery and may eventually have relevance for patient stratification in clinical settings.[9,51] While there was some overlap of DMRs across the symptom domains, the overall pattern suggests disparate methylation signatures, supporting the merit of parsing ADHD into its constituent subtypes.

A key methodological implication of our work is that sex-stratified analyses, despite reduced sample sizes, improve power for identifying associations in phenotypes with pronounced sex differences. The significant sex interaction effects we observed may explain the diminished discovery in our sex-differentiated meta-analyses, as effects present in only one sex are attenuated when groups are combined.[18,47] As shown in our results, epigenome-wide significant DMPs in one sex typically showed no association in the other. Therefore, future epigenetic studies of ADHD and other disorders with sex differences should routinely employ sex-stratified analyses to advance discovery.

The following limitations must be considered when interpreting our findings. First, DNA methylation in cord blood may not directly reflect changes in the brain, limiting the ability to draw causal inferences about central nervous system pathophysiology. However, our goal was to discover early-life peripheral biomarkers of risk, for which cord blood is an accessible tissue. Second, the generalizability of our findings to diverse populations requires further investigation, though we adjusted for ancestry to ensure the inclusion of the minority of MoBa participants from diverse backgrounds. Key strengths include the relatively large sample size and the use of a dimensional measure of ADHD symptoms, which reduces sex biases reported in categorical ADHD diagnoses.

In conclusion, our study provides evidence for sex-specific and subtype-specific cord blood DNA methylation signatures of childhood ADHD, with a distinct profile for females, especially those with inattention symptoms. The findings indicate that peripheral epigenetic correlates of ADHD are evident at birth and show pronounced sex differences. The findings also support sex-stratified approaches to enhance epigenetic discoveries and suggest the potential for these early-life markers to improve early detection, particularly in females with prominent symptoms of inattention. Future research is needed to replicate these findings and assess the predictive value of sex-specific polymethylation scores to advance the development of biomarkers for risk stratification.

Acknowledgments

The Norwegian Mother, Father and Child Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. This research is part of the HARVEST collaboration, supported by the Research Council of Norway (grant 229624). The Norwegian Centre for Mental Disorders Research (NORMENT) provided genotype data, funded by the Research Council of Norway (grant 223273), South East Norway Health Authorities, and Stiftelsen Kristian Gerhard Jebsen. The Center for Diabetes Research, the University of Bergen, provided genotype data funded by the ERC AdG project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, the Trond Mohn Foundation, the Research Council of Norway, the Novo Nordisk Foundation, the University of Bergen, and the Western Norway Health Authorities. We thank Dr. Stephanie London for providing feedback on a previous version of the manuscript. The authors would like to acknowledge support from the Research Council of Norway (RCN) (273291, 273446) and the European Economic Area and Norway Grants (EEA-RO-NO-2018-0573). This work was performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo, operated and developed by the TSD service group at the University of Oslo, IT-Department (USIT) (tsd-drift@usit.uio.no).

Conflict of Interest

The authors have no conflicts of interest to declare.

Availability of Data and Materials

EWAS summary statistics are available from Professor Stephanie Le Hellard, University of Bergen.

CRediT author statement

Markos Tesfaye: Conceptualization, Methodology, Software, Formal analysis, Data curation, Visualization, Project administration, Writing – original draft, Writing – review & editing. **Solveig Løkhammer:** Writing – review & editing, Visualization. **Dinka Smajlagic:** Data curation, Writing – review & editing. **Anne-Kristin Stavrum:** Software, Data curation, Writing – review & editing. **Christian M. Page:** Data curation, Writing – review & editing. **Kira D. Hoeffler:** Software, Writing – review & editing. **Jonelle Villar:** Writing – review & editing, Validation. **Alexey Shadrin:** Software, Writing – review & editing. **Mona Bekkhus:** Writing – review & editing, Data curation. **Tetyana Zayats:** Methodology, Writing – review & editing. **Stephanie Le Hellard:** Conceptualization, Methodology, Writing – review & editing, Resources, Supervision, Funding acquisition.

References

1.   Ayano G, Demelash S, Gizachew Y, Tsegay L, Alati R. The global prevalence of attention deficit hyperactivity disorder in children and adolescents: An umbrella review of meta-analyses. *J Affect Disord*. Oct 15 2023;339:860-866. doi:10.1016/j.jad.2023.07.071

2.   Cortese S, Song M, Farhat LC, et al. Incidence, prevalence, and global burden of ADHD from 1990 to 2019 across 204 countries: data, with critical re-analysis, from the Global Burden of Disease study. *Mol Psychiatry*. Nov 2023;28(11):4823-4830. doi:10.1038/s41380-023-02228-3

3.   Mowlem FD, Rosenqvist MA, Martin J, Lichtenstein P, Asherson P, Larsson H. Sex differences in predicting ADHD clinical diagnosis and pharmacological treatment. *Eur Child Adolesc Psychiatry*. Apr 2019;28(4):481-489. doi:10.1007/s00787-018-1211-3

4.   Martin J, Langley K, Cooper M, et al. Sex differences in attention-deficit hyperactivity disorder diagnosis and clinical care: a national study of population healthcare records in Wales. *J Child Psychol Psychiatry*. Dec 2024;65(12):1648-1658. doi:10.1111/jcpp.13987

5.   Huang CL, Weng SF, Ho CH. Gender ratios of administrative prevalence and incidence of attention-deficit/hyperactivity disorder (ADHD) across the lifespan: A nationwide population-based study in Taiwan. *Psychiatry Res*. Oct 30 2016;244:382-7. doi:10.1016/j.psychres.2016.08.023

6.   Taylor MJ, Martin J, Butwicka A, et al. A twin study of genetic and environmental contributions to attention-deficit/hyperactivity disorder over time. *J Child Psychol Psychiatry*. Nov 2023;64(11):1608-1616. doi:10.1111/jcpp.13854

7.   Faraone SV, Bellgrove MA, Brikell I, et al. Attention-deficit/hyperactivity disorder. *Nat Rev Dis Primers*. Feb 22 2024;10(1):11. doi:10.1038/s41572-024-00495-0

8.   Babinski DE. Sex Differences in ADHD: Review and Priorities for Future Research. *Curr Psychiatry Rep*. Apr 2024;26(4):151-156. doi:10.1007/s11920-024-01492-6

9.   Cecil CAM, Nigg JT. Epigenetics and ADHD: Reflections on Current Knowledge, Research Priorities and Translational Potential. *Mol Diagn Ther*. Nov 2022;26(6):581-606. doi:10.1007/s40291-022-00609-y

10.   Spiers H, Hannon E, Schalkwyk LC, et al. Methylomic trajectories across human fetal brain development. *Genome Res*. Mar 2015;25(3):338-52. doi:10.1101/gr.180273.114

11.   Solomon O, Huen K, Yousefi P, et al. Meta-analysis of epigenome-wide association studies in newborns and children show widespread sex differences in blood DNA methylation. *Mutat Res Rev Mutat Res*. Jan-Jun 2022;789:108415. doi:10.1016/j.mrrev.2022.108415

12.   Neumann A, Walton E, Alemany S, et al. Association between DNA methylation and ADHD symptoms from birth to school age: a prospective meta-analysis. *Transl Psychiatry*. Nov 12 2020;10(1):398. doi:10.1038/s41398-020-01058-z

13.   Walton E, Pingault JB, Cecil CA, et al. Epigenetic profiling of ADHD symptoms trajectories: a prospective, methylome-wide study. *Mol Psychiatry*. Feb 2017;22(2):250-256. doi:10.1038/mp.2016.85

14.   Meijer M, Klein M, Hannon E, et al. Genome-Wide DNA Methylation Patterns in Persistent Attention-Deficit/Hyperactivity Disorder and in Association With Impulsive and Callous Traits. *Front Genet*. 2020;11:16. doi:10.3389/fgene.2020.00016

15.   Rovira P, Sanchez-Mora C, Pagerols M, et al. Epigenome-wide association study of attention-deficit/hyperactivity disorder in adults. *Transl Psychiatry*. Jun 19 2020;10(1):199. doi:10.1038/s41398-020-0860-4

16.   van Dongen J, Zilhao NR, Sugden K, et al. Epigenome-wide Association Study of Attention-Deficit/Hyperactivity Disorder Symptoms in Adults. *Biol Psychiatry*. Oct 15 2019;86(8):599-607. doi:10.1016/j.biopsych.2019.02.016

17.   Mooney MA, Ryabinin P, Wilmot B, Bhatt P, Mill J, Nigg JT. Large epigenome-wide association study of childhood ADHD identifies peripheral DNA methylation associated with disease and polygenic risk burden. *Transl Psychiatry*. Jan 21 2020;10(1):8. doi:10.1038/s41398-020-0710-4

18.   Tesfaye M, Spindola LM, Stavrum AK, et al. Sex effects on DNA methylation affect discovery in epigenome-wide association study of schizophrenia. *Mol Psychiatry*. Aug 2024;29(8):2467-2477. doi:10.1038/s41380-024-02513-9

19.   Magnus P, Birke C, Vejrup K, et al. Cohort Profile Update: The Norwegian Mother and Child Cohort Study (MoBa). *Int J Epidemiol*. Apr 2016;45(2):382-8. doi:10.1093/ije/dyw029

20.   Silva RR, Alpert M, Pouget E, et al. A rating scale for disruptive behavior disorders, based on the DSM-IV item pool. *Psychiatr Q*. Winter 2005;76(4):327-39. doi:10.1007/s11126-005-4966-x

21.   Elliott HR, Tillin T, McArdle WL, et al. Differences in smoking associated DNA methylation patterns in South Asians and Europeans. *Clin Epigenetics*. Feb 3 2014;6(1):4. doi:10.1186/1868-7083-6-4

22.   Zeilinger S, Kuhnel B, Klopp N, et al. Tobacco smoking leads to extensive genome-wide changes in DNA methylation. *PLoS One*. 2013;8(5):e63812. doi:10.1371/journal.pone.0063812

23.   Houseman EA, Accomando WP, Koestler DC, et al. DNA methylation arrays as surrogate measures of cell mixture distribution. *BMC Bioinformatics*. May 8 2012;13:86. doi:10.1186/1471-2105-13-86

24.   Ronningen KS, Paltiel L, Meltzer HM, et al. The biobank of the Norwegian Mother and Child Cohort Study: a resource for the next 100 years. *Eur J Epidemiol*. 2006;21(8):619-25. doi:10.1007/s10654-006-9041-x

25.   Teschendorff AE, Marabita F, Lechner M, et al. A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. *Bioinformatics*. Jan 15 2013;29(2):189-96. doi:10.1093/bioinformatics/bts680

26.   Phipson B, Lee S, Majewski IJ, Alexander WS, Smyth GK. Robust Hyperparameter Estimation Protects against Hypervariable Genes and Improves Power to Detect Differential Expression. *Ann Appl Stat*. Jun 2016;10(2):946-963. doi:10.1214/16-AOAS920

27.   Hoeffler KD, Katrinli, S., Halvorsen, M.W. et al. Optimizing Genetic Ancestry Adjustment in DNA Methylation Studies: A Comaprative Analysis of Approaches. *Research Square (preprint)*. 2025;doi:10.21203/rs.3.rs-6580295/v1

28.   Mansell G, Gorrie-Stone TJ, Bao Y, et al. Guidance for DNA methylation studies: statistical insights from the Illumina EPIC array. *BMC Genomics*. May 14 2019;20(1):366. doi:10.1186/s12864-019-5761-7

29.   Mallik S, Odom GJ, Gao Z, Gomez L, Chen X, Wang L. An evaluation of supervised methods for identifying differentially methylated regions in Illumina methylation arrays. *Brief Bioinform*. Nov 27 2019;20(6):2224-2235. doi:10.1093/bib/bby085

30.   Pedersen BS, Schwartz DA, Yang IV, Kechris KJ. Comb-p: software for combining, analyzing, grouping and correcting spatially correlated P-values. *Bioinformatics*. Nov 15 2012;28(22):2986-8. doi:10.1093/bioinformatics/bts545

31.   Cavalcante RG, Sartor MA. annotatr: genomic regions in context. *Bioinformatics*. Aug 1 2017;33(15):2381-2383. doi:10.1093/bioinformatics/btx183

32.   Gaunt TR, Shihab HA, Hemani G, et al. Systematic identification of genetic influences on methylation across the human life course. *Genome Biol*. Mar 31 2016;17:61. doi:10.1186/s13059-016-0926-z

33.   Kim JH, Kim JY, Lee J, et al. Environmental risk factors, protective factors, and peripheral biomarkers for ADHD: an umbrella review. *Lancet Psychiatry*. Nov 2020;7(11):955-970. doi:10.1016/S2215-0366(20)30312-6

34.   Ma Z, Wang Y, Quan Y, Wang Z, Liu Y, Ding Z. Maternal obesity alters methylation level of cytosine in CpG island for epigenetic inheritance in fetal umbilical cord blood. *Hum Genomics*. Aug 31 2022;16(1):34. doi:10.1186/s40246-022-00410-2

35.   Czamara D, Eraslan G, Page CM, et al. Integrated analysis of environmental and genetic influences on cord blood DNA methylation in new-borns. *Nat Commun*. Jun 11 2019;10(1):2548. doi:10.1038/s41467-019-10461-0

36.   Stover PJ, Field MS. Vitamin B-6. *Adv Nutr*. Jan 2015;6(1):132-3. doi:10.3945/an.113.005207

37. Ng J, Heales SJ, Kurian MA. Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders. *Paediatr Drugs*. Aug 2014;16(4):275-91. doi:10.1007/s40272-014-0079-z

38. Manor I, Newcorn JH, Faraone SV, Adler LA. Efficacy of metadoxine extended release in patients with predominantly inattentive subtype attention-deficit/hyperactivity disorder. *Postgrad Med*. Jul 2013;125(4):181-90. doi:10.3810/pgm.2013.07.2689

39. Olfson E, Farhat LC, Liu W, et al. Rare de novo damaging DNA variants are enriched in attention-deficit/hyperactivity disorder and implicate risk genes. *Nat Commun*. Jul 12 2024;15(1):5870. doi:10.1038/s41467-024-50247-7

40. Faundes V, Newman WG, Bernardini L, et al. Histone Lysine Methylases and Demethylases in the Landscape of Human Developmental Disorders. *Am J Hum Genet*. Jan 4 2018;102(1):175-187. doi:10.1016/j.ajhg.2017.11.013

41. Lebrun N, Mehler-Jacob C, Poirier K, et al. Novel KDM5B splice variants identified in patients with developmental disorders: Functional consequences. *Gene*. Dec 30 2018;679:305-313. doi:10.1016/j.gene.2018.09.016

42. Ferranti AS, Luessen DJ, Niswender CM. Novel pharmacological targets for GABAergic dysfunction in ADHD. *Neuropharmacology*. May 15 2024;249:109897. doi:10.1016/j.neuropharm.2024.109897

43. Puts NA, Ryan M, Oeltzschner G, Horska A, Edden RAE, Mahone EM. Reduced striatal GABA in unmedicated children with ADHD at 7T. *Psychiatry Res Neuroimaging*. Jul 30 2020;301:111082. doi:10.1016/j.pscychresns.2020.111082

44. Martin J, Walters RK, Demontis D, et al. A Genetic Investigation of Sex Bias in the Prevalence of Attention-Deficit/Hyperactivity Disorder. *Biol Psychiatry*. Jun 15 2018;83(12):1044-1053. doi:10.1016/j.biopsych.2017.11.026

45. Taylor MJ, Lichtenstein P, Larsson H, Anckarsater H, Greven CU, Ronald A. Is There a Female Protective Effect Against Attention-Deficit/Hyperactivity Disorder? Evidence From Two Representative Twin Samples. *J Am Acad Child Adolesc Psychiatry*. Jun 2016;55(6):504-512 e2. doi:10.1016/j.jaac.2016.04.004

46. Solberg BS, Hegvik TA, Halmoy A, et al. Sex differences in parent-offspring recurrence of attention-deficit/hyperactivity disorder. *J Child Psychol Psychiatry*. Aug 2021;62(8):1010-1018. doi:10.1111/jcpp.13368

47. Zhou J, Xia Y, Li M, et al. A higher dysregulation burden of brain DNA methylation in female patients implicated in the sex bias of Schizophrenia. *Mol Psychiatry*. Nov 2023;28(11):4842-4852. doi:10.1038/s41380-023-02243-4

48. Hinshaw SP, Nguyen PT, O'Grady SM, Rosenthal EA. Annual Research Review: Attention-deficit/hyperactivity disorder in girls and women: underrepresentation, longitudinal processes, and key directions. *J Child Psychol Psychiatry*. Apr 2022;63(4):484-496. doi:10.1111/jcpp.13480

49. Novik TS, Hervas A, Ralston SJ, et al. Influence of gender on attention-deficit/hyperactivity disorder in Europe--ADORE. *Eur Child Adolesc Psychiatry*. Dec 2006;15 Suppl 1:I15-24. doi:10.1007/s00787-006-1003-z

50. Greven CU, Rijsdijk FV, Plomin R. A twin study of ADHD symptoms in early adolescence: hyperactivity-impulsivity and inattentiveness show substantial genetic overlap but also genetic specificity. *J Abnorm Child Psychol*. Feb 2011;39(2):265-75. doi:10.1007/s10802-010-9451-9

51. Yuan D, Zhang M, Huang Y, Wang X, Jiao J, Huang Y. Noradrenergic genes polymorphisms and response to methylphenidate in children with ADHD: A systematic review and meta-analysis. *Medicine (Baltimore)*. Nov 19 2021;100(46):e27858. doi:10.1097/MD.0000000000027858

Figure Legends

Figure 1. Miami plot showing differentially methylated CpG sites in cord blood associated with total ADHD symptom scores among female and male children in the MoBa cohort. Chromosomes are on the x-axis, -log10 of *p*-values on the y-axis, and the dotted horizontal line represents epigenome-wide significance ($9 \times 10e\text{-}08$).

Figure 2. Venn diagram depicting the overlap of the top 1000 differentially methylated probes in cord blood associated with inattention and hyperactivity/impulsivity in female and male children from the MoBa cohort.

Table 1: Characteristics of MoBa study participant children included in epigenome-wide association study of attention-deficit/hyperactivity disorder (ADHD) symptoms

	MoBa1 (n=655)		MoBa2 (n=330)		MoBa4 (n=896)		MoBa8 (n=491)	
	Male	Female	Male	Female	Male	Female	Male	Female
Sample size (n)	353	302	190	140	443	453	244	247
Gestational age (weeks), mean (SD)	40.0 (1.9)	39.7 (1.8)	39.8 (2.0)	39.5 (1.7)	39.8 (2.0)	39.7 (2.5)	40.0 (2.4)	39.5 (3.1)
Birth weight (kgs), mean (SD) *	3.7 (0.5)	3.5 (0.5)	3.7 (0.5)	3.6 (0.5)	3.6 (0.5)	3.5 (0.5)	3.7 (0.5)	3.6 (0.5)
Cell proportion (%), mean (SD)								
Granulocytes	44.9 (9.5)	47.0 (9.1)	43.9 (9.3)	46.5 (9.5)	44.6 (9.9)	47.3 (9.4)	45.6 (9.5)	47.2 (8.4)
B cells	14.5 (3.8)	14.9 (3.2)	15.0 (3.8)	14.2 (4.0)	13.9 (3.7)	13.2 (3.4)	12.2 (3.9)	11.7 (3.3)
Natural killer cells	4.0 (3.4)	4.2 (3.2)	4.1 (3.4)	4.1 (3.4)	3.6 (3.1)	3.9 (3.1)	1.8 (2.7)	1.9 (2.6)
$CD4^+$ T cells	19.4 (5.1)	19.3 (5.5)	19.5 (5.3)	18.2 (4.7)	18.1 (5.1)	17.7 (5.0)	18.3 (5.8)	17.8 (5.7)
$CD8^+$ T cells	14.8 (5.0)	13.5 (4.4)	14.3 (4.5)	13.7 (4.4)	15.6 (4.8)	13.6 (4.5)	15.3 (4.3)	14.4 (3.9)
Monocytes	10.0 (2.4)	9.5 (2.4)	10.4 (2.3)	10.7 (2.3)	10.2 (2.3)	10.0 (2.2)	9.1 (2.5)	9.4 (2.5)
Smoking scores, mean (SD)	2.4 (2.1)	2.6 (2.1)	1.6 (2.0)	1.7 (2.1)	-0.33 (2.0)	-0.08 (2.0)	0.18 (1.9)	0.39 (1.9)
ADHD score, median (IQR) *	25 (8)	24 (6)	26 (9)	23 (6.5)	26 (8)	24 (7)	25 (8)	23 (6)
Inattention score, median (IQR) *	14 (5)	12 (3)	14 (5)	12 (4)	14 (5)	13 (4)	13 (3.8)	13 (3)
Hyperactivity/impulsivity score, median (IQR) *	12 (4)	11 (3)	12 (5)	11 (3.3)	12 (4)	11 (3)	11 (4)	11 (4)

IQR – Interquartile range; SD – standard deviation
* significant differences between males and females at *p*-value less than 0.05

Probe ID	CHR: Position	Gene	Female only			Male only			Total sample		
			Estimate	SE	P-value	Estimate	SE	P-value	Estimate	SE	P-value
cg01123478	21:31781361		**1.31e-03**	**2.24e-04**	**5.34e-09**	-2.50e-04	1.66e-04	1.32e-01	3.01e-04	1.33e-04	2.39e-02
cg05691806	6:166908677	*RPS6KA2*	**-9.54e-04**	**1.63e-04**	**4.71e-09**	5.33e-05	1.09e-04	6.27e-01	-2.60e-04	9.09e-05	4.18e-03
cg10481534	15:72533779	*PARP6*	**-7.32e-04**	**1.21e-04**	**1.38e-09**	-3.78e-05	3.09e-05	2.21e-01	-8.03e-05	2.99e-05	7.25e-03
cg12934079	1:15527599	*TMEM51*	**-1.41e-03**	**2.43e-04**	**7.33e-09**	-9.73e-06	5.79e-05	8.67e-01	-8.48e-05	5.64e-05	1.32e-01
cg15676735	11:62521955	*ZBTB3*	**9.84e-05**	**1.73e-05**	**1.33e-08**	7.04e-06	1.41e-05	6.17e-01	4.34e-05	1.09e-05	7.06e-05
cg16317998	6:41454329		1.94e-04	1.80e-04	2.82e-01	**-1.46e-03**	**2.66e-04**	**3.90e-08**	-3.26e-04	1.49e-04	2.86e-02
cg27586243	1:83258167		**-8.48e-04**	**1.37e-04**	**6.95e-10**	-5.30e-05	8.26e-05	5.21e-01	-2.64e-04	7.08e-05	1.94e-04
cg01630588	16:65970442		**-5.48e-04**	**1.02e-04**	**7.55e-08**	-7.96e-05	4.11e-05	5.29e-02	-1.45e-04	3.81e-05	1.40e-04
cg20728589	12:132113266		**-6.30e-04**	**1.17e-04**	**7.89e-08**	9.53e-05	5.80e-05	1.00e-01	-4.72e-05	5.20e-05	3.64e-01

Table 2. Cord blood DNA methylation loci associated with ADHD symptoms at age eight in the MOBA study.

Probe ID	CHR: Position	Gene	Female only			Male only			Total sample		
			Estimate	SE	P-value	Estimate	SE	P-value	Estimate	SE	P-value
Inattention symptoms											
cg00152322	15:65198005		**1.39e-03**	**2.59e-04**	**8.47e-08**	-1.01e-04	2.16e-04	6.39e-01	5.08e-04	1.66e-04	2.14e-03
cg01123478	21:31781361		**2.42e-03**	**3.75e-04**	**1.11e-10**	-3.01e-04	2.84e-04	2.90e-01	6.92e-04	2.27e-04	2.24e-03
cg03072921	7:99077090	*ZNF789*	-1.63e-03	3.23e-04	4.26e-07	-7.68e-04	2.90e-04	8.14e-03	**-1.15e-03**	**2.16e-04**	**8.89e-08**
cg07602513	16:22297359	*EEF2K*	**-1.21e-03**	**2.26e-04**	**8.75e-08**	-2.35e-06	4.54e-05	9.59e-01	-4.92e-05	4.45e-05	2.70e-01
cg10481534	15:72533779	*PARP6*	**-1.09e-03**	**2.04e-04**	**7.73e-08**	-8.38e-05	5.50e-05	1.28e-01	-1.53e-04	5.31e-05	4.08e-03
cg12934079	1:15527599	*TMEM51*	**-2.79e-03**	**4.06e-04**	**6.05e-12**	-2.19e-05	1.01e-04	8.29e-01	-1.84e-04	9.83e-05	6.06e-02
cg13328808	1:168230184	*TBX19*	**-2.27e-03**	**4.00e-04**	**1.43e-08**	-7.81e-05	4.19e-05	6.24e-02	-1.02e-04	4.17e-05	1.45e-02
cg14053593	10:103321475		**-1.68e-03**	**2.93e-04**	**1.03e-08**	1.55e-04	8.02e-05	5.37e-02	2.71e-05	7.74e-05	7.26e-01
cg16712581	4:89526335	*HERC3*	**-1.14e-03**	**2.11e-04**	**5.89e-08**	4.58e-04	1.64e-04	5.21e-03	-1.46e-04	1.29e-04	2.59e-01
cg16902958	16:57806838	*KIFC3*	**-1.83e-03**	**3.21e-04**	**1.09e-08**	-2.91e-04	3.32e-04	3.80e-01	-1.09e-03	2.31e-04	2.36e-06
cg16994531	2:11927025	*LPIN1*	**-1.51e-03**	**2.55e-04**	**3.18e-09**	2.19e-05	3.83e-05	5.67e-01	-1.19e-05	3.78e-05	7.54e-01
cg25399998	5:170217126	*GABRP*	**-1.04e-03**	**1.93e-04**	**7.60e-08**	-3.05e-06	1.02e-04	9.76e-01	-2.29e-04	9.01e-05	1.10e-02
cg25661451	11:113200564	*TTC12*	**-2.76e-03**	**4.49e-04**	**7.50e-10**	2.58e-05	2.55e-04	9.19e-01	-6.54e-04	2.22e-04	3.16e-03
cg27586243	1:83258167		**-1.32e-03**	**2.30e-04**	**1.04e-08**	4.80e-05	1.40e-04	7.33e-01	-3.22e-04	1.20e-04	7.13e-03
Hyperactivity/impulsivity symptoms											
cg13426208	2:11795756		-4.10e-04	9.59e-05	1.88e-05	-3.18e-04	8.16e-05	9.86e-05	**-3.56e-04**	**6.21e-05**	**9.56e-09**
cg16317998	6:41454329		-7.74e-05	3.09e-04	8.02e-01	**-2.94e-03**	**4.80e-04**	**9.24e-10**	-9.16e-04	2.60e-04	4.23e-04
cg05928306	14:56351623		**-1.07e-03**	**1.98e-04**	**6.54e-08**	-1.03e-04	6.32e-05	1.02e-01	-1.93e-04	6.02e-05	1.37e-03

Table 3. Cord blood DNA methylation loci associated with inattention and hyperactivity/impulsivity symptoms at age eight in the MOBA Birth study.